GSK

GSK
D

GSK

Arincen73/100B

GSK revenue 1985–2026

GSK's revenue in Q3 FY2026, the three months to 30 September 2026, was 8.82B GBP, up 3.2% on the same quarter a year before. GSK's revenue over the last twelve months was 33.47B GBP, up 4.1% on the twelve months before. In fiscal year 2025 it was 32.67B GBP, up 4.1% on the year before.

Last updated 7 Nov 2026 · Next report 3 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202633.47B+4.06%24.42B4.34B
FY202531 Dec 202532.67B+4.11%23.65B5.72B
FY202431 Dec 202431.38B+3.46%22.33B2.58B
FY202331 Dec 202330.33B+3.42%21.76B4.93B
FY202231 Dec 202229.32B+18.74%19.77B14.96B
FY202131 Dec 202124.70B+1.40%16.53B4.39B
FY202031 Dec 202024.35B-27.85%16.43B5.75B
FY201931 Dec 201933.75B+9.52%21.89B4.65B
FY201831 Dec 201830.82B+2.10%20.58B3.62B
FY201731 Dec 201730.19B+8.24%19.84B1.53B
FY201631 Dec 201627.89B+16.58%18.60B912.00M
FY201531 Dec 201523.92B+3.99%15.07B8.42B
FY201431 Dec 201423.01B-13.20%15.68B2.76B
FY201331 Dec 201326.51B+0.28%17.92B5.44B
FY201231 Dec 201226.43B-3.49%18.51B4.50B
FY201131 Dec 201127.39B-3.54%19.74B5.26B
FY201031 Dec 201028.39B+0.08%20.49B1.63B
FY200931 Dec 200928.37B+16.49%20.99B5.53B
FY200831 Dec 200824.35B+7.10%17.94B4.60B
FY200731 Dec 200722.74B-2.06%17.53B5.22B
FY200631 Dec 200623.22B+7.21%18.21B5.39B
FY200531 Dec 200521.66B+8.40%16.89B4.69B
FY200431 Dec 200419.98B-6.71%15.62B3.91B
FY200331 Dec 200321.41B+0.95%16.88B4.48B
FY200231 Dec 200221.21B+3.30%16.60B3.94B
FY200131 Dec 200120.53B+13.58%16.09B3.10B
FY200031 Dec 200018.08B+112.94%14.12B4.16B
FY199931 Dec 19998.49B+6.35%4.16B1.81B
FY199831 Dec 19987.98B+0.04%6.44B1.84B
FY199731 Dec 19977.98B-4.33%7.98B1.85B
FY199631 Dec 19968.34B-20.49%8.34B2.00B
FY199531 Dec 199510.49B+61.88%10.49B1.46B
FY199430 Jun 19956.48B+14.57%5.58B1.04B
FY199330 Jun 19945.66B+14.73%5.66B1.30B
FY199230 Jun 19934.93B+20.36%4.93B1.21B
FY199130 Jun 19924.10B+20.58%4.10B1.03B
FY199030 Jun 19913.40B+6.86%3.40B881.00M
FY198930 Jun 19903.18B+23.70%3.18B807.00M
FY198830 Jun 19892.57B+24.82%2.57B688.00M
FY198730 Jun 19882.06B+18.27%2.06B581.00M
FY198630 Jun 19871.74B+21.83%1.74B510.00M
FY198530 Jun 19861.43B—1.43B400.00M

Figures in GBP. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

GSK revenue growth by segment

FY2022 against FY2021

Sub Total8.96B
—

GSK revenue by segment over time

Sub Total New And Speciality
Fiscal yearSub TotalNew And Speciality
FY20228.96B —
FY2021— 9.97B

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Income statement

Common questions about GSK's revenue

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.